JP2019534897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534897A5 JP2019534897A5 JP2019541672A JP2019541672A JP2019534897A5 JP 2019534897 A5 JP2019534897 A5 JP 2019534897A5 JP 2019541672 A JP2019541672 A JP 2019541672A JP 2019541672 A JP2019541672 A JP 2019541672A JP 2019534897 A5 JP2019534897 A5 JP 2019534897A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- sensitive polymer
- nanoparticles
- preparation
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 20
- 229940124597 therapeutic agent Drugs 0.000 claims 20
- 238000002360 preparation method Methods 0.000 claims 13
- 239000002105 nanoparticle Substances 0.000 claims 12
- 229920000642 polymer Polymers 0.000 claims 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 3
- 230000002378 acidificating effect Effects 0.000 claims 3
- 239000012736 aqueous medium Substances 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 229920002807 Thiomer Polymers 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/291,480 | 2016-10-12 | ||
| US15/291,480 US11491114B2 (en) | 2016-10-12 | 2016-10-12 | Formulations for enteric delivery of therapeutic agents |
| PCT/US2017/056320 WO2018071655A1 (en) | 2016-10-12 | 2017-10-12 | Formulations for enteric delivery of therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534897A JP2019534897A (ja) | 2019-12-05 |
| JP2019534897A5 true JP2019534897A5 (enExample) | 2020-11-19 |
| JP7046081B2 JP7046081B2 (ja) | 2022-04-01 |
Family
ID=61830540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541672A Active JP7046081B2 (ja) | 2016-10-12 | 2017-10-12 | 治療薬の腸内送達のための製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11491114B2 (enExample) |
| EP (1) | EP3525772A4 (enExample) |
| JP (1) | JP7046081B2 (enExample) |
| KR (2) | KR102580705B1 (enExample) |
| CN (1) | CN110049759A (enExample) |
| AU (2) | AU2017341753B2 (enExample) |
| CA (1) | CA3078570A1 (enExample) |
| WO (1) | WO2018071655A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019097251A1 (en) * | 2017-11-17 | 2019-05-23 | Intract Pharma Limited | Novel compositions |
| KR20210145152A (ko) * | 2019-04-01 | 2021-12-01 | 제넨테크, 인크. | 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들 |
| CN111743880B (zh) * | 2020-06-05 | 2022-03-08 | 浙江大学医学院附属第一医院 | 一种单抗类药物口服纳米-微球制剂及其制备方法 |
| US11365248B2 (en) | 2020-06-29 | 2022-06-21 | Anovent Pharmaceutical (U.S.), Llc | Formulation of tocilizumab and method for treating COVID-19 by inhalation |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| JPS6051106A (ja) * | 1983-08-31 | 1985-03-22 | Yamanouchi Pharmaceut Co Ltd | 塩酸アモスラロ−ル持続性製剤 |
| CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| JPH08507070A (ja) | 1993-02-22 | 1996-07-30 | アルザ・コーポレーション | 活性物質の経口投与のための組成物 |
| EP0766564A4 (en) | 1994-06-24 | 1998-09-23 | Immunex Corp | SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| FR2775435B1 (fr) | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| FR2786098B1 (fr) * | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
| ES2280582T3 (es) | 2001-09-19 | 2007-09-16 | Elan Pharma International Limited | Formulaciones de insulina en nanoparticulas. |
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| WO2005032511A2 (en) * | 2003-09-30 | 2005-04-14 | Spherics, Inc. | Nanoparticulate therapeutic biologically active agents |
| EA200600877A1 (ru) | 2003-10-31 | 2006-12-29 | Тева Фармасьютикал Индастриз, Лтд. | Наночастицы для доставки лекарств |
| KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| US20040224019A1 (en) | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| US7282194B2 (en) | 2004-10-05 | 2007-10-16 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US7291598B2 (en) | 2005-01-04 | 2007-11-06 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US7541028B2 (en) | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for monoclonal antibody delivery |
| CA2621577C (en) | 2005-09-06 | 2013-12-24 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US20090098205A1 (en) | 2005-09-15 | 2009-04-16 | Council Of Scientife & Industrial Research | pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES |
| WO2007036946A1 (en) * | 2005-09-28 | 2007-04-05 | Padma Venkitachalam Devarajan | Compositions for enhanced absorption of biologically active agents |
| KR20090086060A (ko) | 2006-09-12 | 2009-08-10 | 코스모 테크놀러지스 리미티드 | 단백질의 경구 또는 직장 투여를 위한 약학적 조성물 |
| AU2007333528B2 (en) | 2006-10-05 | 2013-10-17 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
| US20100062073A1 (en) | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
| EP2178518A2 (en) | 2007-07-13 | 2010-04-28 | Bend Research, Inc | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| EP2240162A4 (en) | 2007-12-06 | 2013-10-09 | Bend Res Inc | NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER |
| CN102083423A (zh) | 2008-05-06 | 2011-06-01 | 葛兰素集团有限公司 | 生物活性剂的囊封方法 |
| CN102083419A (zh) * | 2008-07-01 | 2011-06-01 | 日东电工株式会社 | 包含表面被覆了的微粒的医药组合物 |
| US20100021549A1 (en) | 2008-07-28 | 2010-01-28 | Flamel Technologies, S.A. | Microparticle oral form useful for the modified release of nanoparticles |
| FR2934161B1 (fr) | 2008-07-28 | 2010-09-17 | Flamel Tech Sa | Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules. |
| GB0815852D0 (en) | 2008-09-01 | 2008-10-08 | Unilever Plc | Improvements relating to pharmaceutical compositions |
| WO2010113177A2 (en) | 2009-03-31 | 2010-10-07 | Reliance Life Sciences Pvt. Ltd. | Oral insulin delivery systems for controlling diabetes |
| US8673359B2 (en) | 2010-07-08 | 2014-03-18 | Brown University | Nanoparticle compositions and methods for improved oral delivery of active agents |
| CN102614498B (zh) * | 2011-01-28 | 2014-12-17 | 四川科伦药物研究有限公司 | 一种胰岛素纳米粒及其制备方法 |
| US20140120162A1 (en) | 2011-06-06 | 2014-05-01 | Perosphere Inc. | Bioadhesive Drug Delivery Compositions |
| EP2548571A1 (en) * | 2011-07-22 | 2013-01-23 | Institut Curie | Compositions having means for targeting at least one antigen to dendritic cells |
| CN102908332B (zh) * | 2011-08-04 | 2014-04-16 | 纳米及先进材料研发院有限公司 | 用于口服胰岛素递送的包含阳离子纳米粒子的肠溶包衣胶囊 |
| US8859004B2 (en) | 2011-08-04 | 2014-10-14 | Nano And Advanced Materials Institute Limited | pH-sensitive nanoparticles for oral insulin delivery |
| US9101547B2 (en) | 2011-08-04 | 2015-08-11 | Nano And Advanced Materials Institute Limited | Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery |
| KR20190077124A (ko) | 2011-10-21 | 2019-07-02 | 스템제닉스 인코포레이티드 | 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 |
| ES2946549T3 (es) | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Composición farmacéutica de nilotinib |
| EP3778696A1 (en) | 2012-04-23 | 2021-02-17 | NanoProteagen Ltd. | Polymeric nanoparticles and a process of preparation thereof |
| CA3159085A1 (en) * | 2013-01-14 | 2014-07-17 | Clinics Operations Limited | Combination cancer therapeutics and uses thereof |
| US9833522B2 (en) * | 2013-12-23 | 2017-12-05 | The Research Foundation For The State University Of New York | Graphene-based contrast agents for photoacoustic and thermoacoustic tomography and method of use |
| JP6651507B2 (ja) | 2014-05-30 | 2020-02-19 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 抗原結合性分子のナノ封入 |
| US9370488B2 (en) | 2014-07-21 | 2016-06-21 | Kimia Zist Parsian | Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin |
| PT107846B (pt) | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
| WO2016115234A1 (en) | 2015-01-14 | 2016-07-21 | Board Of Regents, The University Of Texas System | Hydrogels for delivery of therapeutic compounds |
| CN104739806B (zh) * | 2015-04-17 | 2018-04-03 | 黑龙江大学 | 口服胰岛素复合微囊及制备方法 |
| CN105056212B (zh) * | 2015-07-14 | 2018-06-15 | 江西省药物研究所 | 一种提高胰岛素口服结肠吸收的壳聚糖纳米粒及制备方法 |
-
2016
- 2016-10-12 US US15/291,480 patent/US11491114B2/en active Active
-
2017
- 2017-10-12 CA CA3078570A patent/CA3078570A1/en active Pending
- 2017-10-12 CN CN201780076441.1A patent/CN110049759A/zh active Pending
- 2017-10-12 WO PCT/US2017/056320 patent/WO2018071655A1/en not_active Ceased
- 2017-10-12 KR KR1020197013487A patent/KR102580705B1/ko active Active
- 2017-10-12 EP EP17860772.7A patent/EP3525772A4/en active Pending
- 2017-10-12 JP JP2019541672A patent/JP7046081B2/ja active Active
- 2017-10-12 KR KR1020237031642A patent/KR20230135694A/ko active Pending
- 2017-10-12 AU AU2017341753A patent/AU2017341753B2/en active Active
-
2022
- 2022-10-03 US US17/958,815 patent/US20230034964A1/en active Pending
-
2024
- 2024-03-05 AU AU2024201438A patent/AU2024201438A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Applications of polymer-based nanoparticles in vaccine field | |
| Pawar et al. | Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response | |
| Chen et al. | Enhanced humoral and cell-mediated immune responses generated by cationic polymer-coated PLA microspheres with adsorbed HBsAg | |
| Vasquez-Martínez et al. | The role of mucoadhesion and mucopenetration in the immune response induced by polymer-based mucosal adjuvants | |
| Yao et al. | Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity | |
| He et al. | Cyclodextrin/chitosan nanoparticles for oral ovalbumin delivery: Preparation, characterization and intestinal mucosal immunity in mice | |
| JP5546532B2 (ja) | 非免疫原生の疎水性タンパク質ナノ粒子の形成方法、及びその利用 | |
| Xu et al. | Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives | |
| CN1993113B (zh) | 包含磷酸钙纳米颗粒核心，生物分子和胆汁酸的颗粒，其生产方法，其治疗用途 | |
| Urban et al. | Nanotools for the delivery of antimicrobial peptides | |
| JP2011521662A5 (enExample) | ||
| Wu et al. | Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery | |
| JP2019534897A5 (enExample) | ||
| Lemoine et al. | Technological approaches for improving vaccination compliance and coverage | |
| JP2015519330A5 (enExample) | ||
| RU2014128590A (ru) | Применение полимерных эксципиентов для лиофилизации или заморозки частиц | |
| Rana | Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges | |
| Jorquera et al. | Synthetic biodegradable microparticle and nanoparticle vaccines against the respiratory syncytial virus | |
| WO2021189678A1 (zh) | 一种全细胞组分的输送系统及其应用 | |
| Mangal et al. | Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system (s) administered intranasally | |
| CN114288397A (zh) | 基于多种癌细胞和/或肿瘤组织全细胞组分的预防或治疗癌症的疫苗系统及其制备与应用 | |
| Li et al. | Mannan-decorated thiolated Eudragit microspheres for targeting antigen presenting cells via nasal vaccination | |
| JP2015512441A5 (enExample) | ||
| CN114288398B (zh) | 基于全细胞组分的癌症疫苗系统在制备交叉预防或治疗异种癌症药物中的应用 | |
| Ftouh et al. | Contribution of nanotechnologies to vaccine development and drug delivery against respiratory viruses |